TRICARE Xarelto Prior Authorization: Navigating Regional Requirements

Successfully managing TRICARE Xarelto prior authorization is critical for patient access to direct oral anticoagulants. Klivira automates the complex, region-specific submission processes.

For revenue cycle directors and prior authorization coordinators, navigating TRICARE's decentralized structure for high-volume medications like Xarelto (rivaroxaban) presents unique challenges. Efficiently securing prior authorizations requires precise understanding of regional contractor workflows and policy application, directly impacting patient care continuity and revenue integrity.

Understanding Xarelto (Rivaroxaban) within TRICARE

Xarelto, or rivaroxaban, is a direct oral anticoagulant (DOAC) indicated for conditions such as atrial fibrillation and venous thromboembolism (VTE). As with many high-cost or high-risk medications, TRICARE plans typically require prior authorization to ensure medical necessity. Formulary tier placement for rivaroxaban can vary, and some TRICARE plans may implement step therapy requirements before approval.

TRICARE's Regionalized Prior Authorization Process for DOACs

TRICARE, administered by the Defense Health Agency (DHA), routes prior authorization submissions through its regional contractors. For beneficiaries in the TRICARE East region, workflows are managed by Humana Military. For those in the TRICARE West region, submissions route through TriWest Healthcare Alliance's provider channels. This regionalization means distinct operational processes for Xarelto PA requests.

Key Considerations for TRICARE Xarelto PA Submissions

  • **Regional Contractor Gateways:** Submissions must align with the specific provider portal or electronic channels of Humana Military (TRICARE East) or TriWest (TRICARE West).
  • **Medical Policy Adherence:** TRICARE medical policies, available via tricare.mil, provide the clinical criteria for rivaroxaban. These policies are then operationally implemented by the regional contractors.
  • **Network Status Impact:** A beneficiary's network status (e.g., TRICARE Prime vs. TRICARE Select) can influence the scope of PA requirements and referral pathways.
  • **Clinical Documentation:** Comprehensive documentation supporting the diagnosis (atrial fibrillation, VTE) and medical necessity, including any prior treatment failures for step therapy, is essential.

Streamlining TRICARE Xarelto Prior Authorization with Klivira

Klivira's platform is engineered to navigate the complexities of TRICARE's regionalized prior authorization landscape. Our system identifies the appropriate regional contractor—Humana Military for TRICARE East or TriWest for TRICARE West—and routes Xarelto PA requests directly through their respective portals. This integration reduces manual effort and accelerates submission timelines for rivaroxaban.

Automating Policy Application and Submission Logic

Beyond routing, Klivira layers TRICARE's specific medical policy framework with the regional contractor's utilization management operations. Our automation capabilities help ensure that submitted documentation aligns with TRICARE's clinical criteria for Xarelto, minimizing common discrepancies that lead to delays or denials. This proactive approach supports higher first-pass approval rates for rivaroxaban PAs.

Frequently asked questions

How does TRICARE handle prior authorizations for Xarelto (rivaroxaban)?

TRICARE processes Xarelto prior authorizations through its regional contractors: Humana Military for TRICARE East and TriWest Healthcare Alliance for TRICARE West. Each contractor manages submissions via their own provider portals and operational channels, adhering to TRICARE's overarching medical policies for direct oral anticoagulants.

What clinical documentation is typically required for Xarelto PA with TRICARE?

For Xarelto (rivaroxaban), TRICARE typically requires clinical documentation supporting the indicated use, such as confirmed diagnosis of atrial fibrillation or venous thromboembolism (VTE). If step therapy is applicable, documentation of previous treatment failures or contraindications to preferred agents may also be necessary to demonstrate medical necessity.

Where can I find TRICARE's medical policies for Xarelto?

TRICARE's general medical policies for medications, including those for direct oral anticoagulants like Xarelto, are published on tricare.mil. It is important to cross-reference these policies with any regional-contractor-specific operational implementations or forms provided by Humana Military or TriWest.

Does Klivira integrate directly with Humana Military and TriWest for Xarelto PAs?

Yes, Klivira's platform is designed to integrate with the operational channels of TRICARE's regional contractors. For Xarelto prior authorizations, Klivira identifies the beneficiary's region and routes submissions directly through the responsible contractor's portal, whether it's Humana Military for TRICARE East or TriWest for TRICARE West.

Can Klivira help with Xarelto step therapy requirements for TRICARE beneficiaries?

Klivira's automation platform is built to support complex utilization management requirements, including step therapy. By integrating with payer policy libraries and facilitating comprehensive data submission, Klivira helps ensure that all necessary documentation regarding prior treatment history or contraindications is included for Xarelto PA requests, aligning with TRICARE's step therapy criteria.

Related coverage

Other xarelto prior authorization by payer

Other xarelto prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo